Safety finding weighs on Pfizer's inflammation drug, and could spell trouble for others

A large safety study has found that patients given Xeljanz, a Pfizer drug approved for various inflammatory diseases, had health issues like major heart complications and cancer at a higher incidence than those who got a different kind of anti-inflammation drug. The results could spell trouble for Xeljanz and other drugs that work in a similar way, according to analysts.